Elicio Therapeutics Reports Q2 2026 Financial Results with Reduced Net Loss

Elicio Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $8.2 million, a decrease from a net loss of $10.6 million in the same period last year. For the six months ended June 30, 2026, the company recorded a net loss of $20.0 million, compared to $21.8 million for the first half of 2025. The reduction in losses is attributed to a decrease in research and development expenses, which fell to $6.8 million in Q2 2026 from $7.0 million in Q2 2025, primarily due to lower clinical trial costs as the Phase 2 study of ELI-002 7P progressed into the follow-up phase.

Total operating expenses for the second quarter of 2026 were $10.4 million, a slight increase from $10.1 million in the prior year. General and administrative expenses rose to $3.6 million, up from $3.1 million, driven by increased personnel costs associated with a higher headcount. The company’s cash and cash equivalents stood at $23.5 million as of June 30, 2026, an increase from $18.6 million at the end of 2025, bolstered by net proceeds of approximately $24.4 million from common stock issuances under its at-the-market programs.

Elicio's strategic developments include the ongoing evaluation of its lead product candidate, ELI-002 7P, which targets mKRAS-positive pancreatic cancer. The Phase 2 AMPLIFY-7P trial did not meet its primary endpoint but showed early treatment benefits in certain patient subgroups. The company plans to refine its Phase 3 development strategy based on these findings and intends to initiate a Phase 1 study evaluating ELI-002 7P in combination with a RAS small molecule inhibitor. This study is expected to begin in the fourth quarter of 2026.

The company has faced significant challenges, including an accumulated deficit of $253.7 million as of June 30, 2026, and ongoing operating losses. Elicio has indicated substantial doubt about its ability to continue as a going concern, emphasizing the need for additional financing to support its operations and product development. The company plans to address its liquidity needs through public offerings, private placements, and potential collaborations, although there is no assurance that these efforts will be successful.

Looking ahead, Elicio anticipates continued increases in research and development and general administrative expenses as it advances its clinical programs and prepares for potential commercialization. The company expects its cash reserves to fund operations into the first quarter of 2027, contingent on its current financial operating plan. However, it acknowledges that any significant changes in spending or progress could alter this timeline.